Bedaquiline HCl

• CAT Number: I023138
• Molecular Formula: C32H32BrClN2O2
• Molecular Weight: 591.97
• Purity: 98%
• Synonyms: TMC-207;TMC 207; TMC207; R207910; AIDS222089; AIDS-222089; AIDS 222089; Bedaquiline fumarate
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol;hydrochloride
• InChI: InChI=1S/C32H31BrN2O2.ClH/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3;/h4-17,20-21,30,36H,18-19H2,1-3H3;1H/t30-,32-;/m1./s1
• InChIKey: AOJCUQGSVYCVQU-UNCJQMLCSA-N
• SMILES: CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O.Cl

Bedaquiline HCl（Cat No.:I023138）is a novel antimicrobial agent used in the treatment of multidrug-resistant tuberculosis (MDR-TB). It works by inhibiting the mycobacterial ATP synthase, an enzyme essential for the energy production in Mycobacterium tuberculosis, the bacteria responsible for tuberculosis. By disrupting energy production, Bedaquiline interferes with bacterial growth and replication, aiding in the fight against resistant strains. Approved by the FDA, Bedaquiline is typically used in combination with other anti-TB drugs. While effective, its use requires monitoring for potential side effects, including liver toxicity and QT prolongation in the heart.